Accuray (NSDQ:ARAY) said it inked a deal with RaySearch Laboratories to allow Accuray to co-market RaySearch’s RayCare oncology information system in several designated major radiation therapy markets
RayCare is designed to handle logistical challenges present in modern radiation therapy centers by using high-performance radiation therapy algorithms, Sunnyvale, Calif.-based Accuray said.
“In today’s complex healthcare environment it is becoming increasingly important to deliver clinical excellence and successful outcomes for cancer patients through radiation treatment options, which are both effective and efficient. Our goal in partnering with RaySearch is to provide solutions that will enhance the integration of the TomoTherapy and CyberKnife technologies with our customers’ oncology department workflow, enabling them to more easily manage the large volumes of clinical data and to streamline their patients’ radiation treatments,” Accuray CEO Joshua Levine said in a press release.
The system also has advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy, Accuray said. The system is expected to be released in 2017.
“The RaySearch and Accuray collaboration agreement brings together 2 companies dedicated to providing clinicians with innovative solutions which result in more effective radiation therapy for cancer patients. We believe RayCare has the potential to set a new standard for oncology information systems and will enable cancer centers to optimize their workflow and use of resources to maximize the level of care they provide to their patients,” RaySearch CEO Johan Lof said in prepared remarks.
Last September, Accuray landed an exclusive contract to offer its CyberKnife M6 and TomoTherapy HDA devices to members of Premier Inc. at special rates, saying it hoped the deal would “significantly increase visibility” for its devices.